Clinical trials: Advanced Gastric Adenocarcinoma
Gastric Adenocarcinoma
Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients
Gastric cancer remains one of the major causes of cancer deaths around the world,especially in Asia. For advanced gastric cancer,even if treated with chemotherapy,the prognosis is still poor, so the investigators urgently need an…
- Trial name
- NCT01641783
- Testing
- nanoparticle Albumin-Bound paclitaxel
- Volunteers
- 40 people
- Sponsor
- Yanqiao Zhang
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Adenocarcinoma
Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI
This trial will be conducted to evaluate the efficacy, safety and tolerability of SUNITINIB as add-on therapy with a widely used second-line palliative FOLFIRI chemotherapy in patients with chemo-refractory advanced or metastatic…
- Trial name
- SUN-CASE (NCT01020630)
- Testing
- Sunitinib
- Where
- 16 sites in Germany
- Volunteers
- 91 people
- Sponsor
- PD Dr Markus Möhler
Adenocarcinoma - GEJ, Adenocarcinoma of the Stomach
A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric
This is a single-arm, open-label, clinical study to evaluate the safety of HER2 tumor vaccine injection alone/in combination with standard of care chemotherapy in patients with HER2/neu overexpressing gastric or gastroesophageal…
- Trial name
- NCT05315830
- Testing
- HER2 Tumor Vaccine, HER2 Tumor Vaccine+ Standard of Care chemotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
This is a Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects with Previously Treated Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced…
- Trial name
- G-HOPE-001 (NCT06238843)
- Testing
- Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）, IBI343
- Where
- 95 sites in China, Japan
- Volunteers
- 464 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hepatoid Adenocarcinoma of Stomach
Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach
The goal of this clinical trial is to learn if treatment modality including albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules (SOX) and sintilimab works to treat locally advanced…
- Trial name
- HASCHANGE02 (NCT07178340)
- Testing
- Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Gastric Adenocarcinoma
Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer
The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer.
- Trial name
- NCT06798376
- Testing
- 2-4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy, 5-8 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy, Gastrectomy
- Where
- China
- Volunteers
- 409 people
- Sponsor
- Chinese PLA General Hospital
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus standard second-line chemotherapy.
- Trial name
- NCT04385550
- Testing
- Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection
- Where
- 45 sites in China
- Volunteers
- 528 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
The goal of this study is to evaluate the efficacy and safety of oral paclitaxel solution plus fruquintinib as second-line therapy in adult subjects with advanced or metastatic gastric (G) or gastroesophageal junction (GEJ)…
- Trial name
- FREEDOM (NCT07552402)
- Testing
- Oral Paclitaxel Solution Plus Fruquintinib, Investigator Choice (IC) Chemotherapy
- Where
- 15 sites in China
- Volunteers
- 150 people
- Sponsor
- Harbin Medical University
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Advanced Gastric Carcinoma, CD8+ Tumor Infiltrating Lymphocytes
Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma
Focusing on the clinical question of whether patients with advanced gastric cancer can benefit from immunotherapy, this project intends to detect the degree of CD8+ tumor-infiltrating lymphocyte infiltration in patients with…
- Conditions
- Advanced Gastric Carcinoma, CD8+ Tumor Infiltrating Lymphocytes, Neoadjuvant Immunotherapy
- Trial name
- NCT05270824
- Testing
- radical surgery after neoadjuvant immunotherapy, radical surgery after neoadjuvant chemotherapy
- Volunteers
- 120 people
- Sponsor
- Fujian Medical University
Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma
This is an open-label, prospective, interventional study designed to enroll 34 patients with locally advanced gastric or gastroesophageal junction adenocarcinoma, aiming to evaluate and observe the efficacy and safety of QL1706…
- Trial name
- NCT07828873
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), Docetaxel, Oxaliplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastrointestinal Neoplasms, Adenocarcinoma
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131.
- Trial name
- NCT02795988
- Testing
- IMU-131, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
- Where
- 22 sites in Georgia, India and 5 more
- Volunteers
- 64 people
- Sponsor
- Imugene Limited
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Gastrointestinal Tract Malignancies
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and…
- Trial name
- EDGE-Gastric (NCT05329766)
- Testing
- Domvanalimab, Quemliclustat, Zimberelimab
- Where
- 43 sites in United States, Canada and 4 more
- Volunteers
- 332 people
- Sponsor
- Arcus Biosciences, Inc.
Pancreatic Cancer
Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma
This trial will assess the MTD and RP2D of SOT102 administered as monotherapy (Part A) and in combination with first-line SoC treatment (nab-paclitaxel/ gemcitabine; Part B) and efficacy of SOT102 administered as monotherapy…
- Trial name
- CLAUDIO-01 (NCT05525286)
- Testing
- SOT102
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 31 people
- Sponsor
- SOTIO Biotech a.s.
Metastatic HER2 Positive Gastroesophageal Junction Cancer
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
This study will find the maximum tolerated dose (MTD) of CYNK-101 which contains Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Trial name
- NCT05207722
- Testing
- CYNK-101, Pembrolizumab, Trastuzumab
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Celularity Incorporated
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Gastro-oesophageal Junction Cancer, Gastric Cancer
Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer
The purpose of this study is to assess the efficacy, safety and tolerability of AZD4547 compared with paclitaxel in patients with advanced gastric or lower-oesophageal cancer whose tumours are found to have FGFR2 polysomy or gene…
- Trial name
- SHINE (NCT01457846)
- Testing
- AZD4547, paclitaxel
- Where
- 61 sites in Belgium, Bulgaria and 14 more
- Volunteers
- 960 people
- Sponsor
- AstraZeneca